ASH 2015

Final OS Analysis of Panorama 1 Trial of Panobinostat/Bortezomib/Dexamethasone in RRMM

Conference Correspondent - ASH 2015 - Multiple Myeloma

The randomized, placebo-controlled phase 3 PANORAMA 1 trial demonstrated that panobinostat, a potent pan-deacetylase inhibitor, in combination with bortezomib/dexamethasone (PAN/BTZ/Dex) resulted in significant prolongation of progression-free survival (PFS) of approximately 4 months compared with placebo plus bortezomib/dexamethasone (Pbo/BTZ/Dex) in patients [ Read More ]

Bortezomib/Melphalan/Prednisolone Induction Therapy Followed by Lenalidomide/Dexamethasone Consolidation and Lenalidomide Maintenance in Transplant-Ineligible Patients with Newly Diagnosed MM

Conference Correspondent - ASH 2015 - Multiple Myeloma

Ishida and colleagues reported interim results of a phase 2 trial that evaluated reduced- intensity bortezomib/melphalan/prednisolone (VMP) followed by lenalidomide/low-dose dexamethasone (Rd) consolidation therapy and lenalidomide maintenance therapy to improve outcomes of transplant-ineligible patients with newly diagnosed multiple myeloma (MM). [ Read More ]

Rituximab, Lenalidomide, and Ibrutinib as Frontline Therapy in Follicular Lymphoma: Results of the ALLIANCE 051103 Phase 1 Study

Conference Correspondent - ASH 2015 - Castleman’s Disease, Lymphoma, and CLL

Ongoing clinical efforts are focused on evaluating the efficacy and tolerability of targeted therapies in patients with follicular lymphoma (FL). Previous trials have separately demonstrated the safety and antitumor activity of the combination of rituximab with the immunomodulatory drug lenalidomide [ Read More ]

Outcomes of Ibrutinib Treatment in Patients with Relapsed or Refractory CLL/SLL with del17p in the RESONATE-17 Study

Conference Correspondent - ASH 2015 - Castleman’s Disease, Lymphoma, and CLL

Patients with chronic lymphocytic leukemia (CLL) harboring deletion 17p (del17p) cytogenetic abnormalities are associated with poor prognosis, and show suboptimal responses to chemoimmunotherapy, underscoring the need for novel treatment strategies. Ibrutinib is a first-in-class, oral inhibitor of Bruton’s tyrosine kinase [ Read More ]